JPS61103897A - Preparation of anti-carpaine - Google Patents

Preparation of anti-carpaine

Info

Publication number
JPS61103897A
JPS61103897A JP59225486A JP22548684A JPS61103897A JP S61103897 A JPS61103897 A JP S61103897A JP 59225486 A JP59225486 A JP 59225486A JP 22548684 A JP22548684 A JP 22548684A JP S61103897 A JPS61103897 A JP S61103897A
Authority
JP
Japan
Prior art keywords
formula
leu
compound
group
alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP59225486A
Other languages
Japanese (ja)
Other versions
JPH0548237B2 (en
Inventor
Takashi Murachi
村地 孝
Takaharu Tanaka
隆治 田中
Naoki Higuchi
直樹 樋口
Masayuki Saito
雅之 齊藤
Masaki Hashimoto
昌樹 橋本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kawaken Fine Chemicals Co Ltd
Suntory Ltd
Original Assignee
Kawaken Fine Chemicals Co Ltd
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kawaken Fine Chemicals Co Ltd, Suntory Ltd filed Critical Kawaken Fine Chemicals Co Ltd
Priority to JP59225486A priority Critical patent/JPS61103897A/en
Publication of JPS61103897A publication Critical patent/JPS61103897A/en
Publication of JPH0548237B2 publication Critical patent/JPH0548237B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

NEW MATERIAL:The compound of formula I (R is -CH2-S-CH3, -CH2-CH2-CH3 or group of formula II). EXAMPLE:The compound of formula III. USE:An anticarpaine compound. It exhibits strong enzymeinhibiting activity against carpaine, and little inhibiting activity to serine protease. PREPARATION:The objective compound of formula I can be prepared by suspending the ester of formula IV (R' is methyl or ethyl) in a tert-alcohol, adding a reducing agent such as sodium borohydride, adding anhydrous methanol to the mixture under refluxing in an inert gas atmosphere, and oxidizing the resultant alcohol of formula V with sulfur trioxide-pyridine complex in dimethyl sulfoxide. The starting compound of formula IV is synthesized by conventional peptide synthesis using corresponding amino acids or peptides.

Description

【発明の詳細な説明】 (産業上の利用分野) 本発明はカルパインに対して強い酵素阻害活性を示す抗
カルパイン化合物ならびに該化合物の合成法に関するも
のである。
DETAILED DESCRIPTION OF THE INVENTION (Industrial Application Field) The present invention relates to an anti-calpain compound that exhibits strong enzymatic inhibitory activity against calpain, and a method for synthesizing the compound.

(従来技術) カルパイン(E、C,5,4,22,171Calpa
in )ht。
(Prior art) Calpain (E, C, 5, 4, 22, 171 Calpa
in ) ht.

ジスティングロチアーゼの一種であるが、このカルパイ
ンの活性化が難病である筋ジストロフィーの原因と考え
られて匹ろ。従って筋ジストロフィーの治療薬としてカ
ルパインの活性?特異的に阻害する薬剤の開発が望まれ
ている。また、カルパインやハハインに代表されるシス
テインプコテアーゼ活性%を特異的に阻害する薬剤は、
抗災症剤としての用途の上からも開発が望まれている。
Calpain, a type of dystingulothiase, is thought to be the cause of the intractable disease muscular dystrophy. Therefore, is calpain active as a therapeutic agent for muscular dystrophy? The development of drugs that specifically inhibit this is desired. In addition, drugs that specifically inhibit cysteine pcotease activity %, such as calpain and hahain,
Its development is also desired for its use as an anti-disaster drug.

カルパイン田害物質としては、先に清水らにより合成さ
れたロイペプチン(3himizu、B、ら。
As a calpain field-damaging substance, leupeptin, which was previously synthesized by Shimizu et al.

J 、 Antib iot ics l 25巻、5
15頁(1972)1及び本発明者らが放−−の培養液
より抽出精製したストレビンp−1(′¥9願昭58−
ii6616号明細V)が知られているか、これはカル
パイン。
J, Antib iotics l vol. 25, 5
15 (1972) 1 and Strevin p-1 ('¥9 Gansho 58-
ii6616 Specification V) is known, which is calpain.

パイパン等のジスティングロチアーゼだけでなく、トリ
プシン、プラスミン等のセリンプロテアーゼの酵素活性
も阻害するため、その特異性に欠け。
It lacks specificity because it inhibits not only distingufacturing proteases such as Paipan but also serine proteases such as trypsin and plasmin.

筋ジストロフィー等の治療薬として十分満足すべきもの
ではない。
It is not fully satisfactory as a therapeutic agent for muscular dystrophy, etc.

(発明の目的) そこで本発明者らは、ジスティングロチアーゼ。(Purpose of the invention) Therefore, the present inventors developed distingufacturing prothiase.

特にカルパインに対する阻害作用が強く、しかもセリン
プロテアーゼに対しては全く阻害作用乞示さない化合物
馨見出すべく檀々合成研究した結果。
This is the result of extensive synthetic research aimed at finding a compound that has a particularly strong inhibitory effect on calpain, but has no inhibitory effect on serine proteases.

本発明乞完成した。The invention has been completed.

(発明の構成) 本発明の抗カルバイン活性乞有する化合物は次    
  fの一般式I: (式中、Rは−CH2−8−CH3、−CH2−CH2
−CH3以下便宜上、上記式I中5Rが一〇H2−8−
CH3のものをSUAM312.−CH2−CH2−C
H3のものSUAM314  と呼ぶ。
(Structure of the Invention) The compound having anti-carbaine activity of the present invention is as follows.
General formula I of f: (wherein R is -CH2-8-CH3, -CH2-CH2
-CH3 or less For convenience, 5R in the above formula I is 10H2-8-
The CH3 one is SUAM312. -CH2-CH2-C
The H3 one is called SUAM314.

本発明の化合物は清水らのロイペプチンと類似するが、
アルデヒド末端がアルギニン出来のものでない点で構造
的に異なっている。
The compounds of the present invention are similar to leupeptin of Shimizu et al.
It is structurally different in that the aldehyde end is not made of arginine.

本発明の化合物の合成は、一般的ペプチド合成法により
行うことができるが、以下に説明する本発明の合成法に
よれば都合よく合成されろ。なお、各略号は仄の意味2
表わす: Z:ペンジルオキ7カルボニル基、 Leu :ロイシン残基。
Although the compounds of the present invention can be synthesized by general peptide synthesis methods, they are conveniently synthesized by the synthetic methods of the present invention described below. In addition, each abbreviation has the meaning 2
Represents: Z: penzylox7carbonyl group, Leu: leucine residue.

OEt:エチルエステル基、 M、et:メチオニン残基 nLeu :ノルロイシン残基。OEt: ethyl ester group, M, et: methionine residue nLeu: Norleucine residue.

OMe:メチルエステル基、 Acニアセチル基。OMe: methyl ester group, Ac Niacetyl group.

WSCI :N−エチル−N′・N′−ジメチルアミノ
プロピルカルポジイミド。
WSCI: N-ethyl-N'.N'-dimethylaminopropylcarpodiimide.

TEAニトリエチルアミン、 BF −0Et2:三フッ化ホウ素エーテル錯体。TEA nitriethylamine, BF-0Et2: boron trifluoride ether complex.

なお、合成例において、N末端のアミン基ケアセチル基
で保強しているが、他の適当なアシル基やウレタン型の
保護基で保護してもよい。
In the synthesis examples, the N-terminal amine group is protected by a careacetyl group, but it may be protected by other suitable acyl groups or urethane-type protecting groups.

本発明の合成法により5式Iの化合物Y製造するには、
次の一般式ll: 1式中、RI工前記式Iで与えられた意味2表わし、R
′ はメチル基又はエチル基を表わす、)で表わさハ、
ろエステル乞〉)三アルコールに馨濁し、不活注気体中
で還流下無水メタノール乞滴下することにより次の一般
式III: で表わされるアルコールに変換し1次いで該アルコール
をジメチルスルホキシド中、二酸化イオウ−ピリジン錯
体で酸化する。
To prepare compound Y of formula I by the synthetic method of the present invention,
The following general formula 11: In the formula 1, the meaning given in the RI formula I is represented by 2, R
' represents a methyl group or an ethyl group,
(filtered ester)) Dissolved in a trialcohol and added dropwise to anhydrous methanol under reflux in an inert gas atmosphere to convert it into an alcohol represented by the following general formula III: -oxidize with pyridine complexes.

弐〇で表わされる出発物質は、常法によりアミノ末Aを
Z基等の保護基で保護した相当するアミノ酸又はペプチ
ドと、カルボキシ末端をエステル基等で保護した相当す
るアミノ酸又はペプチドとを適宜反応させて得ろことが
できる。
The starting material represented by 2 is obtained by appropriately reacting a corresponding amino acid or peptide with the amino terminal A protected with a protecting group such as a Z group, and a corresponding amino acid or peptide with the carboxy terminal protected with an ester group, etc. using a conventional method. Let's get what we can.

以下、実施例により本発明をさらに詳しく説明するO 参考例(式Uで表わされる出発物質の合成)!11  
Ac−Leu−Leu−Met−OMeの合成a) Z
−Leu−Leu−OEt Z−Leu−OH(1当it ) 、 Leu−OEt
 eHct(1当量)及びTEA(1当り=に乾燥塩化
メチレンに溶解し、水冷下にWSCT(1当量)を加え
る。
Hereinafter, the present invention will be explained in more detail with reference to Examples. Reference Example (Synthesis of starting material represented by formula U)! 11
Synthesis of Ac-Leu-Leu-Met-OMe a) Z
-Leu-Leu-OEt Z-Leu-OH (1 unit), Leu-OEt
Dissolve eHct (1 eq.) and TEA (1 eq.) in dry methylene chloride and add WSCT (1 eq.) under water cooling.

室温で16時間攪拌したのち、反応液乞1N塩酸、水、
飽和重曹水及び飽和食塩水で洗い、無水硫酸マグネシウ
ムで乾燥する。#媒ケ減圧留去して目的化合物の結晶を
得7−5 b)  Z−Leu−Leu −0H z−Leu−Leu−OEt (1当量)?メタノール
に俗解し、1N水酸化ナトリウム(2当t)fjx加え
、室温で2時間攪拌する5反応数?減圧譲縮したのち、
1N堰rilY加えて酸性とし、酢酸エチルで抽出する
。抽出液を飽和食塩水で洗い、無水硫酸マグネシウムで
乾燥したのち、溶媒を減圧留去       !し、目
的化合物の結晶を得る。
After stirring at room temperature for 16 hours, the reaction solution was mixed with 1N hydrochloric acid, water,
Wash with saturated sodium bicarbonate solution and saturated saline solution, and dry with anhydrous magnesium sulfate. The # solvent was distilled off under reduced pressure to obtain crystals of the target compound 7-5 b) Z-Leu-Leu -0H z-Leu-Leu-OEt (1 equivalent)? 5 Reactions: Add 1N sodium hydroxide (2 equivalents) fjx to methanol, and stir at room temperature for 2 hours. After decompression concessions,
Acidify by adding 1N weir rilY and extract with ethyl acetate. After washing the extract with saturated saline and drying over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure! and obtain crystals of the target compound.

c)  Z−Leu−Leu−Met−OMeZ−Le
u−Leu−OH(1当量)、M e t −Qp、1
6 @)]C6(1当量)及びTEA(1当量)を乾燥
塩化メチレンに溶解し、水冷下にWSCI(1当量)r
t加えろ、室温で16時間攪拌したのち1反応液ゲ1N
塩ビ、水、飽和重曹水及び飽和食塩水で洗い。
c) Z-Leu-Leu-Met-OMeZ-Le
u-Leu-OH (1 equivalent), M e t -Qp, 1
6@)] C6 (1 eq.) and TEA (1 eq.) were dissolved in dry methylene chloride, and WSCI (1 eq.) was added under water cooling.
After stirring at room temperature for 16 hours, add 1N to the reaction solution.
Wash PVC, water, saturated sodium bicarbonate solution, and saturated salt solution.

無水硫酸マグネシウムで乾燥する。溶媒を減圧留去し目
的化合物の結晶を得る。
Dry with anhydrous magnesium sulfate. The solvent is distilled off under reduced pressure to obtain crystals of the target compound.

d)  Ac  Leu−Leu−Met −OMeZ
−Leu−Leu−Met −OMe (1当量)ヲ乾
燥メタノールに浴解し、パラジウムカーボン(少量)と
BF  ・0Et2(約3当量)Y:加えて、接触還元
によりZ基?除去する5反応液をろ過したのち。
d) Ac Leu-Leu-Met-OMeZ
-Leu-Leu-Met -OMe (1 equivalent) was dissolved in dry methanol, palladium carbon (a small amount) and BF ・0Et2 (approximately 3 equivalents) Y: In addition, Z group ? 5 After filtering the reaction solution to be removed.

減圧留去して得られた残渣を、乾燥堪化メチレンに一ヤ
;濁させ、無水酢酸乞加えろ。室温で16時間攪拌した
のち、反応液を減EE!縮して得られた残瀘乞l8rF
、酸エチルに浴解させ、水、飽和重曹水及び飽和賞塩水
で洗う。無水値1設マグネシウムで乾燥し、沼1に?減
圧留去して目的化合物の結晶乞得ろ。
The residue obtained by distillation under reduced pressure is suspended in dry diluted methylene, and then acetic anhydride is added. After stirring at room temperature for 16 hours, the reaction solution was reduced to EE! The residue obtained by shrinking l8rF
, dissolved in ethyl acid and washed with water, saturated sodium bicarbonate solution and saturated brine. Dry with anhydrous value 1 set magnesium and swamp 1? Distill under reduced pressure to obtain crystals of the target compound.

(21Ac  Leu−Leu−nLeu−OEtの合
成a)  Z−Leu−Leu−nLeu−OEtZ−
Leu−Leu−OH(1当量)、nLeu OEt・
HC/、(i当り、TEA(1当量)?乾燥塩化メチレ
ンに#解し、氷冷下にWSCI(1当量)を加える。室
温で16時間攪拌したのち、反応液t1N塩酸1 *、
飽和重曹水及び飽和食塩水で洗い。
(Synthesis a of 21Ac Leu-Leu-nLeu-OEt) Z-Leu-Leu-nLeu-OEtZ-
Leu-Leu-OH (1 equivalent), nLeu OEt・
HC/, (per i, TEA (1 equivalent)? Dissolved in dry methylene chloride, add WSCI (1 equivalent) under ice cooling. After stirring at room temperature for 16 hours, the reaction solution was t1N hydrochloric acid 1*,
Wash with saturated sodium bicarbonate solution and saturated saline solution.

無水億酸マグネシウムで乾燥する。溶媒乞減圧留去し、
目的化合物の結晶?得る。
Dry with anhydrous magnesium chloride. Remove the solvent under reduced pressure,
Crystals of the target compound? obtain.

b) Ac−Leu −Leu−nLeu−OEtZ−
Leu−Leu−nLeu−OEt Yメタノールに浴
解し、水、酢酸、およびパラジウムカーボンな加えて、
接触還元によりZ基を除去する5反応液?ろ過したのち
、減圧留去して得られた残渣?乾燥クロロホルムに浴W
4させ、乾“、東ベンゼン及び無水酢酸を加えろ、室温
で16時□間攪拌したのち。
b) Ac-Leu -Leu-nLeu-OEtZ-
Leu-Leu-nLeu-OEt Y was dissolved in methanol, in addition to water, acetic acid, and palladium on carbon.
5 reaction solutions for removing Z group by catalytic reduction? The residue obtained after filtration and distillation under reduced pressure? Bath in dry chloroform
4, add dry benzene, and acetic anhydride, and stir at room temperature for 16 hours.

反応液?減圧濃縮して得られた残渣2酢酸エチルに俗解
させ、水5飽和重曹水及び飽和食塩水で洗う、無水伝醒
マグネシウムで乾燥し、#媒を減圧留去して、目的化合
物の結晶を得ろ。
Reaction liquid? The residue obtained by concentration under reduced pressure was dissolved in ethyl diacetate, washed with water, 5 saturated sodium bicarbonate solution and saturated brine, dried over anhydrous transferred magnesium, and the solvent # was distilled off under reduced pressure to obtain crystals of the target compound. .

t31  Ac−Leu−、T、eu−OEtの合成a
)  Z−Leu−Leu−Leu−OEtZ−Leu
−Leu −OH(1当t ) 、 Leu−OEt 
・HC4(1当量)、TEA(1肖鴬)′l:!:乾燥
塩化メチVンに冶燐し、氷冷下にWSCI(1当量)乞
加えろ、室温で16時間攪拌したのち、反応液?1N塩
酸、水、鉋相寅曲水及び飽和食塩水で洗い、無水#C敵
マグネシウムで乾燥する。6媒を減圧留去し、目的化せ
物の結晶?得る。
t31 Synthesis of Ac-Leu-, T, eu-OEta
) Z-Leu-Leu-Leu-OEtZ-Leu
-Leu -OH (1t), Leu-OEt
・HC4 (1 equivalent), TEA (1 equivalent)'l:! : Pyrophorize dry methylene chloride, add WSCI (1 equivalent) under ice cooling, stir at room temperature for 16 hours, and then add the reaction solution. Wash with 1N hydrochloric acid, water, water, and saturated saline, and dry with anhydrous #C magnesium. The 6 medium is distilled off under reduced pressure and crystals of the target substance are obtained? obtain.

b)Ac−Leu−Leu−Lcu−OEtZ−Leu
−Leu Leu−OEtyメタノールvc(g解し、
水、酢酸、およびパラジウムカーボンを加えて、陛触還
冗によりZ基を除去するう反応漱をろ過したのち、減圧
留去して得られた残漬ン乾燥クロロホルムに俗解させ、
彰、詠ベンゼン及び無水酢酸乞加え7:)。室温で16
時間攪拌したのち、反応/!グ?減EE娘縮して得られ
た残欣乞戸敗し、冷酢敵エチルで洸い目的化合物乞結晶
として得ろ。
b) Ac-Leu-Leu-Lcu-OEtZ-Leu
-Leu Leu-OEty methanol vc (g.
Water, acetic acid, and palladium on carbon were added, and the reaction residue was filtered to remove the Z group by evaporation, and then distilled under reduced pressure to leave the resulting residue in dry chloroform.
Akira, Eibenzene and acetic anhydride added 7:). 16 at room temperature
After stirring for an hour, the reaction/! Gu? Discard the residue obtained by reducing the EE daughter and obtain it as a crystal of the desired compound with cold vinegar and ethyl chloride.

実J4汐1.1  (SUAM312ρ合成)   4
a)八c−Leu7Leu−Met−oL(SUAM3
12の−CI−10の代りに−CH20Hを有する中間
体)参考例(1)で得たAc−Leu−Leu−Met
 −OMe(866mg、2ミリモル)と水素化ホウ表
ナトリウム(190/Q、5ミlJモル)乞第三ブチル
アルコール(16づ)にtJ!濁させ、窒素気流下に加
熱攪拌し5次いで還流上無水メタノール(2,4m1)
ビ滴下した。、滴下終了後、1時間還流攪拌したのち室
温にもどし5氷冷下に水(10+nl’)Y加えた。
Real J4 Shio 1.1 (SUAM312ρ synthesis) 4
a) 8c-Leu7Leu-Met-oL (SUAM3
Intermediate having -CH20H instead of -CI-10 in 12) Ac-Leu-Leu-Met obtained in Reference Example (1)
-OMe (866 mg, 2 mmol) and sodium borohydride (190/Q, 5 ml J mol) were added to tJ! The mixture was made cloudy, heated and stirred under a nitrogen stream, and then refluxed with anhydrous methanol (2.4 ml).
I dripped it. After completion of the dropwise addition, the mixture was stirred under reflux for 1 hour, then returned to room temperature, and water (10+nl') Y was added thereto while cooling with ice.

メタノールと第三ブチルアルコール2減圧留去した後、
酢酸エチルで3回抽出し、飽和食塩水で洗浄して、無水
硫酸マグネシウムで乾燥した。酢酸エチル?減圧留去し
て得られた粗結晶乞酢鍛エチルからp5結晶し、目的化
合物(520rny、64憾)乞得た。
After methanol and tert-butyl alcohol were distilled off under reduced pressure,
It was extracted three times with ethyl acetate, washed with saturated brine, and dried over anhydrous magnesium sulfate. Ethyl acetate? The target compound (520rny, 64ml) was obtained by crystallizing p5 from the crude ethyl crystals obtained by distillation under reduced pressure.

b)SUAM312 Ac −Leu−Leu−Met −oL (404m
? 、1ミリモル)とトリエチルアミン(0,56mA
、4ミリモル)馨無水ジメチルスルホキシド(4,2d
)に溶かし、攪拌下に三酸化イオウ−ピリジン錯体(6
67!n9・4ミリモル)のジメチルスルホキシ   
  fド(4m/)溶液?加えた。室温で10分攪拌後
、氷水(30d)に注ぎ、酢酸エチルで3回抽出し。
b) SUAM312 Ac -Leu-Leu-Met -oL (404m
? , 1 mmol) and triethylamine (0,56 mA
, 4 mmol) Kaoru anhydrous dimethyl sulfoxide (4,2d
) and stirred with sulfur trioxide-pyridine complex (6
67! n9・4 mmol) of dimethyl sulfoxy
f-do(4m/) solution? added. After stirring at room temperature for 10 minutes, the mixture was poured into ice water (30d) and extracted three times with ethyl acetate.

10チクエン酸水溶液、水、飽和重曹水及び飽和食塩水
で洗浄し、無水硫酸マグネシウムで乾燥した。酢酸エチ
ルを減圧留去して得られた粗結晶乞酢酸エチルから再結
晶し、次式で表わされろSUAM312(300m91
75% )Y得た。
It was washed with an aqueous solution of 10 citric acid, water, a saturated aqueous sodium bicarbonate solution and a saturated saline solution, and dried over anhydrous magnesium sulfate. The crude crystals obtained by distilling off ethyl acetate under reduced pressure were recrystallized from ethyl acetate to obtain SUAM312 (300m91
75%)Y obtained.

得らねた化合物の物性は、後記表1に示す。。The physical properties of the obtained compound are shown in Table 1 below. .

実施例2  (SUAM3.13の合M、)a) Ac
−Leu−Leu−nLeu−oLc SUAM313
の−CH0の代りに−CH20H乞有する中間体)参考
例(2)で得たAc−Leu−Leu−nLeu70E
t(556η11.6ミリモル)と水素化ホウ素ナトリ
ウム(123In9・3.25ミリモル)を第三ブチル
アルコール(12m7)に懸濁させ、窒素気流下に加熱
攪拌し1次いで還流上無水メタノール(1,8d)を滴
下した。滴下終了後1時間還流攪拌したのち1温にもど
し、水冷下に水(10mAりY加えた。
Example 2 (SUAM3.13 combination M,) a) Ac
-Leu-Leu-nLeu-oLc SUAM313
Ac-Leu-Leu-nLeu70E obtained in Reference Example (2)
t (556η11.6 mmol) and sodium borohydride (123In9.3.25 mmol) were suspended in tert-butyl alcohol (12 m7), heated and stirred under a nitrogen stream, and then refluxed with anhydrous methanol (1.8 d ) was added dropwise. After the dropwise addition was completed, the mixture was refluxed and stirred for 1 hour, then returned to 1 temperature, and water (10 mA) was added while cooling with water.

メタノールと第三ブチルアルコール?減圧留去した後、
酢酸エチルで3回抽出し、飽和食塩水で洗浄して無水硫
酸マグネシウムで乾燥した。酢酸エチルを減圧留去して
得られた粗結晶を酢酸エチルから再結晶し、目的化合物
(210%l・42チ)?得た。
Methanol and tertiary butyl alcohol? After distilling off under reduced pressure,
It was extracted three times with ethyl acetate, washed with saturated brine, and dried over anhydrous magnesium sulfate. The crude crystals obtained by distilling off ethyl acetate under reduced pressure were recrystallized from ethyl acetate to obtain the target compound (210% 1, 42 ml). Obtained.

b)SUAM313 Ac−Leu−Leu−nLeu−ot(193m9 
+ 0.5ミリモル)とトリエチルアミン(0,2M 
、 2.0ミリモル)を無水ジメチルスルホキシド(2
d)に浴かし、攪拌下に三酸化イオウ−ピリジン錯体(
520/n9,2.0ミリモル)のジメチルスルホキシ
ド(21nl)溶液を加えた。室温で10分間攪挿抜氷
水(30mA)に注ぎ、酢酸エチルで3回抽出し、10
LSクエン酸水溶液、水、飽和重曹水及び飽和食塩水で
洗浄し、無水硫酸マグネシウムで乾燥した。酢酸エチル
を減圧留去して得られた粗結晶を酢酸エチルから再結晶
し、次式で表わされろSUAM315(901n9,4
7% )Y得た。
b) SUAM313 Ac-Leu-Leu-nLeu-ot (193m9
+ 0.5 mmol) and triethylamine (0.2 M
, 2.0 mmol) in anhydrous dimethyl sulfoxide (2.0 mmol)
d) and add the sulfur trioxide-pyridine complex (
A solution of 520/n9, 2.0 mmol) in dimethyl sulfoxide (21 nl) was added. Stir for 10 minutes at room temperature, pour into ice water (30 mA), extract 3 times with ethyl acetate,
It was washed with an aqueous LS citric acid solution, water, a saturated aqueous sodium bicarbonate solution, and a saturated saline solution, and dried over anhydrous magnesium sulfate. The crude crystals obtained by distilling off ethyl acetate under reduced pressure were recrystallized from ethyl acetate to obtain SUAM315 (901n9,4
7%)Y obtained.

H3 得られた化合物の物性は、後記表2に示す。H3 The physical properties of the obtained compound are shown in Table 2 below.

実施例3  (SUAM314の合成)a) Ac−L
eu−Leu−Leu−ol (SUAM 3 j 4
の−CH0の代りに−CH20Hw有する中間体)参考
eiIJ+31で得たAc−Leu−Leu−Leu−
OEt(8551W、1.3ミリモル)と水素化ホウ素
ナトリウム(19QIn9・5ミリモル)を第三ブチル
アルコール(16m)に懸濁させ、窒累気流下に加熱攪
拌し、次いで還流下無水メタノール(2,4IILl)
2柄下した。滴下終了後、1時間還流攪拌したのち室温
にもどし、水冷下に水10m1)’Y加えた。
Example 3 (Synthesis of SUAM314) a) Ac-L
eu-Leu-Leu-ol (SUAM 3 j 4
Intermediate with -CH20Hw instead of -CHO of ) Ac-Leu-Leu-Leu- obtained in reference eiIJ+31
OEt (8551W, 1.3 mmol) and sodium borohydride (19QIn 9.5 mmol) were suspended in tert-butyl alcohol (16m), heated and stirred under a nitrogen stream, and then dissolved in anhydrous methanol (2,5 mmol) under reflux. 4IILl)
2 hilts were lowered. After the dropwise addition was completed, the mixture was stirred under reflux for 1 hour, then returned to room temperature, and 10 ml of water was added while cooling with water.

メタノールと第三ブチルアルコールχ減圧留去した後、
酢酸エチルで3回抽出し、飽和食塩水で洗浄して無水硫
酸iグネシウムで乾燥した。酢酸エチルを減圧留去して
得られた粗結晶ケ酢酸エチルから再結晶し、目的化合物
(490rn9.64%)乞得た。
After distilling methanol and tert-butyl alcohol χ under reduced pressure,
The extract was extracted three times with ethyl acetate, washed with saturated brine, and dried over anhydrous magnesium sulfate. The crude crystals obtained by distilling off ethyl acetate under reduced pressure were recrystallized from ethyl acetate to obtain the target compound (490rn9.64%).

b)SUAM314 Ac−Leu−Leu−Leu −ol (386m?
 + 1ミリモル)とトリエチルアミン(Q、5(5m
1.4ミリモル)を無水ジメチルスルホキシド(4,2
a/りに溶かし、攪拌下に三酸化イオウ−ピリジン錯体
(637In9.4ミリモル)のジメチルスルホキシド
(4M)溶液を加えた。室温で10分間攪拌後。
b) SUAM314 Ac-Leu-Leu-Leu -ol (386m?
+ 1 mmol) and triethylamine (Q, 5 (5 m
1.4 mmol) in anhydrous dimethyl sulfoxide (4,2
A solution of sulfur trioxide-pyridine complex (637In 9.4 mmol) in dimethyl sulfoxide (4M) was added under stirring. After stirring for 10 minutes at room temperature.

氷水(30a/ )に注ぎ、酢酸エチルで6回抽出し、
10%クエン酸水浴液、水、飽和重曹水及び飽和食塩水
で洗浄し、無水硫酸マグネシウムで乾燥した。酢酸エチ
ルを減EE留去して得られた粗結晶ケ酢酸エチルから再
結晶し、次式で表わされるSUAM314(260ダ・
68チ)?得た。
Pour into ice water (30a/ml), extract 6 times with ethyl acetate,
It was washed with a 10% citric acid aqueous solution, water, saturated sodium bicarbonate solution and saturated brine, and dried over anhydrous magnesium sulfate. The crude crystals obtained by distilling off ethyl acetate under reduced EE were recrystallized from ethyl acetate to obtain SUAM314 (260 Da.
68chi)? Obtained.

SUAM314 得られた化合物の物性は、後記表6に示す。SUAM314 The physical properties of the obtained compound are shown in Table 6 below.

=79 実施例4 本発明物質の生理活性 本発明物質の酵素阻害活性は以下のように測定された。=79 Example 4 Physiological activity of the substance of the present invention The enzyme inhibitory activity of the substance of the present invention was measured as follows.

本発明物質と酵素溶液とを混合し、60℃で5分間プレ
インキュベイトしてから基質浴液を混合して反応?開始
させろ。基質として0.5憾カゼインを用い、その他に
5mhA塩化カルシウム、10mMシスティン及び50
 mM ) IJスー塩酸緩衝液rpH7,5)’?加
え、30℃で60分間反応させる。
The substance of the present invention and the enzyme solution are mixed, pre-incubated at 60°C for 5 minutes, and then the substrate bath solution is mixed and reacted. Let it start. 0.5mhA casein was used as a substrate, and 5mhA calcium chloride, 10mM cysteine, and 50mHA calcium chloride were used as substrates.
mM) IJ-HCl buffer rpH7,5)'? Add and react at 30°C for 60 minutes.

次いで反応WLlfC6,5%トリクロル酢酸を1えて
反応Y停止させ、酵素により加水分′Sされたカゼイン
のトリクロロ酢酸可溶画分中のタンパク量をローリー−
フォリン(Lowry−Fol in )法により測定
し、対照液との対比から1slI害能ぞ求める。
Next, reaction WLlfC6.5% trichloroacetic acid was added to stop the reaction, and the amount of protein in the trichloroacetic acid soluble fraction of casein that had been hydrolyzed by the enzyme was determined by low concentration.
It is measured by the Lowry-Folin method, and the harmful activity of 1slI is determined from comparison with a control solution.

こうして得られたカルパイン■、カルパインa及びパパ
インに対す′ろ本発明物質の活性阻害作用をロイペプチ
ン及びストレピンP1の作用と対比して表4及び図に示
す。
The inhibitory effects of the substances of the present invention on the thus obtained calpain Ⅰ, calpain a and papain are shown in Table 4 and the figure in comparison with the effects of leupeptin and strepin P1.

本発明物質はカルパインL及びカルバインUに対して夫
々0.05〜10μ?で50チ以上の阻害活性を示すこ
とが判明した。
The substance of the present invention is 0.05 to 10μ for calpain L and calvine U, respectively. It was found that the inhibitory activity was more than 50%.

さらに、上記方法により本発明物質のセリンプロテアー
ゼ(トリプシン・プラスミン)に対する阻害作用Tf:
W++定したところ%冶んど阻害作用は認められなかっ
た。 ・
Furthermore, by the above method, the inhibitory effect Tf of the substance of the present invention on serine protease (trypsin/plasmin):
When W++ was determined, no inhibition of % hardening was observed.・

【図面の簡単な説明】[Brief explanation of drawings]

囚は本発明物質とロイペプチンのカルパインUに対する
活性阻害効果を示すグラフである。 特許出願人 サントリー株式会社 (外5名) 阻S割の量 (p(1/試騒管〕 手  続  補  正  書 昭和60年8月ノ2日 1、事件の表示 昭和59年特許願@  225486  号2、発明の
名称 抗カルパインの製造法 3、補正をする者 事件との関係  特許出願人 住所 名 亦  (190)  サントリー株式会社4代 理
 人 5、補正の対象 明細書の〔特許請求の範囲〕と〔発明の詳細な説明〕の
欄(別紙) (1)特許請求の範囲を次のとおシ補正する。 「(1)次の一般式I: (式中、R(z =CH2−S−CHa、−CH2−C
H2−CHaで表わされる化合物。 (2)次の一般式■: (式中、Rは下記式Iで与えられる意flt’al−表
わし R/はメチル基又はエチル基を衣ゎす。)で表わ
されるエステルを第三アルコールに懸濁メタノールを添
加することによ9次の一般式■:で表わされるアルコー
ルに変換し、次いテ該アルコールをジメチルスルホキシ
ド甲、三酸化イオウ−ピリジン錯体で酸化することより
なる、次の一般式I: (式中、R+z−CH2−8−CH3、−CH2−CH
2−CH3で表わされる化合物の製造方法。」 (2)明a書、第6頁末行の と補正する。 (3)  同第10頁第18行の「(3) Ac−Le
u−Leu−OEtO合戎」をj (3J  Ac−L
eu−Leu−Leu−OEtの合成」と補正する。 (4)同第17頁第1行の と補正する。 (5)同第7頁第3行〜4行の「に懸濁し、不活性気体
中」を「に懸濁し、X素化ホウ素ナトリウム等の還元剤
を加え、不活性気体中」と補正する。
Figure 3 is a graph showing the inhibitory effect of the substance of the present invention and leupeptin on the activity of calpain U. Patent Applicant: Suntory Limited (5 others) Amount of Inhibition S Percentage (p (1/Test Tube)) Procedure Amendment Written August 2, 1985 1, Incident Indication 1982 Patent Application @ 225486 No. 2, Name of the invention Process for producing anti-calpain 3, Relationship with the case of the person making the amendment Patent applicant's address 亦 (190) Suntory Ltd. 4 Agent Person 5: [Claims of the specification to be amended] ] and [Detailed Description of the Invention] column (attachment) (1) The scope of the claims is amended as follows: "(1) The following general formula I: (wherein, R(z = CH2-S -CHa, -CH2-C
A compound represented by H2-CHa. (2) The following general formula ■: (wherein, R represents the meaning given by the following formula I; R/ represents a methyl group or an ethyl group) to a tertiary alcohol. By adding suspended methanol, it is converted into an alcohol represented by the following general formula (1), and then the alcohol is oxidized with dimethyl sulfoxide (A) and a sulfur trioxide-pyridine complex. Formula I: (wherein R+z-CH2-8-CH3, -CH2-CH
A method for producing a compound represented by 2-CH3. (2) Amended from the last line of page 6 of Book A. (3) “(3) Ac-Le” on page 10, line 18 of the same
j (3J Ac-L
eu-Leu-Leu-OEt”. (4) Amend the same as on page 17, line 1. (5) On page 7, lines 3 and 4, amend "suspended in, in an inert gas" to "suspended in, added a reducing agent such as sodium boroboronate, and in an inert gas." .

Claims (2)

【特許請求の範囲】[Claims] (1)次の一般式 I : ▲数式、化学式、表等があります▼( I ) (式中、Rは−CH_2−S−CH_3、−CH_2−
CH_2−CH_3又は▲数式、化学式、表等がありま
す▼の基を表わす。) で表わされる化合物。
(1) The following general formula I: ▲There are mathematical formulas, chemical formulas, tables, etc.▼(I) (In the formula, R is -CH_2-S-CH_3, -CH_2-
Represents the group CH_2-CH_3 or ▲, which has mathematical formulas, chemical formulas, tables, etc. ) A compound represented by
(2)次の一般式II: ▲数式、化学式、表等があります▼(II) (式中、Rは下記式 I で与えられる意味を表わし、R
′はメチル基又はエチル基を表わす。) で表わされるエステルを第三アルコールに懸濁し、不活
性気体中で還流下無水メタノールを添加することにより
次の一般式III: ▲数式、化学式、表等があります▼(III) で表わされるアルコールに変換し、次いで該アルコール
をジメチルスルホキシド中、三酸化イオウ−ピリジン錯
体で酸化することよりなる、次の一般式 I : ▲数式、化学式、表等があります▼( I ) (式中、Rは−CH_2−S−CH_3、−CH_2−
CH_2−CH_3又は▲数式、化学式、表等がありま
す▼の基を表わす。) で表わされる化合物の製造方法。
(2) The following general formula II: ▲There are mathematical formulas, chemical formulas, tables, etc.▼(II) (In the formula, R represents the meaning given in the following formula I, and R
' represents a methyl group or an ethyl group. ) is suspended in a tertiary alcohol and anhydrous methanol is added under reflux in an inert gas to form the alcohol represented by the following general formula III: and then oxidizing the alcohol with a sulfur trioxide-pyridine complex in dimethyl sulfoxide according to the following general formula I: ▲Mathematical formulas, chemical formulas, tables, etc.▼(I) (wherein R is -CH_2-S-CH_3, -CH_2-
Represents the group CH_2-CH_3 or ▲, which has mathematical formulas, chemical formulas, tables, etc. ) A method for producing a compound represented by
JP59225486A 1984-10-26 1984-10-26 Preparation of anti-carpaine Granted JPS61103897A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP59225486A JPS61103897A (en) 1984-10-26 1984-10-26 Preparation of anti-carpaine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59225486A JPS61103897A (en) 1984-10-26 1984-10-26 Preparation of anti-carpaine

Publications (2)

Publication Number Publication Date
JPS61103897A true JPS61103897A (en) 1986-05-22
JPH0548237B2 JPH0548237B2 (en) 1993-07-20

Family

ID=16830077

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59225486A Granted JPS61103897A (en) 1984-10-26 1984-10-26 Preparation of anti-carpaine

Country Status (1)

Country Link
JP (1) JPS61103897A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013549A1 (en) * 1991-02-07 1992-08-20 Research Corporation Technologies, Inc. Inhibition of cell proliferation by hydrophobic peptides
WO1992014696A2 (en) * 1991-02-22 1992-09-03 The Du Pont Merck Pharmaceutical Company SUBSTITUTED α-AMINOALDEHYDES AND DERIVATIVES
EP0520336A2 (en) * 1991-06-19 1992-12-30 FUJIREBIO Inc. Aldehyde derivatives and their use as calpain inhibitors
US5444042A (en) * 1990-12-28 1995-08-22 Cortex Pharmaceuticals Method of treatment of neurodegeneration with calpain inhibitors
WO2006092326A2 (en) * 2005-03-03 2006-09-08 Technische Universität Darmstadt Mimetic peptides and the use thereof in the form of 20s, 26s and immunoproteasome inhibitors

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444042A (en) * 1990-12-28 1995-08-22 Cortex Pharmaceuticals Method of treatment of neurodegeneration with calpain inhibitors
WO1992013549A1 (en) * 1991-02-07 1992-08-20 Research Corporation Technologies, Inc. Inhibition of cell proliferation by hydrophobic peptides
WO1992014696A2 (en) * 1991-02-22 1992-09-03 The Du Pont Merck Pharmaceutical Company SUBSTITUTED α-AMINOALDEHYDES AND DERIVATIVES
EP0520336A2 (en) * 1991-06-19 1992-12-30 FUJIREBIO Inc. Aldehyde derivatives and their use as calpain inhibitors
WO2006092326A2 (en) * 2005-03-03 2006-09-08 Technische Universität Darmstadt Mimetic peptides and the use thereof in the form of 20s, 26s and immunoproteasome inhibitors
WO2006092326A3 (en) * 2005-03-03 2006-12-07 Univ Darmstadt Tech Mimetic peptides and the use thereof in the form of 20s, 26s and immunoproteasome inhibitors
US8835392B2 (en) 2005-03-03 2014-09-16 Technische Universität Mimetic peptides and the use thereof in the form of 20S, 26S and immunoproteasome inhibitors

Also Published As

Publication number Publication date
JPH0548237B2 (en) 1993-07-20

Similar Documents

Publication Publication Date Title
JP2701932B2 (en) Protease inhibitor
Ohno et al. Reduction by a model of NAD (P) H. 25. A chiral model which induces high asymmetry
US5091406A (en) Prolinal derivatives
JPS6259296A (en) Peptide derivative
HU217612B (en) Process for producing peptides of elastaze- and cathepsin-g-inhibitor activity
JPS62129278A (en) Novel pyrrolidinylimide ester derivative having inhibitory activity against prolylendopeptidase, production and use thereof
JPS61103897A (en) Preparation of anti-carpaine
JPS63264454A (en) Novel prolinal derivative, production thereof and antiamnesic agent containing said derivative
JPS61183297A (en) Novel peptide compound having proline endopeptidase inhibitor activity
JPH0629229B2 (en) Cysteine proteinase inhibitor
JPH10502050A (en) N-[{4,5-dihydroxy- and 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracen-yl} carbonyl] amino acids useful in the treatment of osteoarthritis
US3891692A (en) N-(cyclopropylalkoxycarbonyl)amino acids
IL44973A (en) 3-(rho-chlorobenzoyl)-2-methylphenyl acetic acid derivatives,process for preparing them and pharmaceutical compositions containing them
JP2001139534A (en) Valine derivative and its use
JPS606958B2 (en) Antibiotic purification method
JPS6048506B2 (en) Guanidinobenzoic acid derivatives
Balenović et al. Pseudoconhydrine; Direct Correlation of the Configuration at C (2) with that of α-Amino Acids
JPS62242692A (en) Production of moranoline derivative
JPH04117396A (en) Tripeptide derivative having pyroglutamic acid residue
JPH05213990A (en) Tripeptide derivative
JPH035379B2 (en)
ATSUUMI et al. Renin inhibitors. II. Synthesis and structure-activity relationships of N-terminus modified inhibitors containing a homostatine analogue
JPH0260595A (en) Production of alpha-hydroxy-beta-amino acid derivative
JPS61238799A (en) Novel compound with inhibitory action production and use thereof
JPH0623191B2 (en) Peptidase-inhibiting active compound, its production method and use

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term